KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Non-Current Deffered Revenue: 2020-2025

Historic Non-Current Deffered Revenue for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $5.8 million.

  • AbCellera Biologics' Non-Current Deffered Revenue fell 27.78% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year decrease of 27.78%. This contributed to the annual value of $5.7 million for FY2024, which is 30.45% down from last year.
  • Latest data reveals that AbCellera Biologics reported Non-Current Deffered Revenue of $5.8 million as of Q3 2025, which was down 49.71% from $11.6 million recorded in Q2 2025.
  • AbCellera Biologics' Non-Current Deffered Revenue's 5-year high stood at $64.8 million during Q2 2022, with a 5-year trough of $5.7 million in Q4 2024.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $8.6 million (2024), whereas its average is $12.7 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first soared by 123.29% in 2022, then plummeted by 73.66% in 2023.
  • AbCellera Biologics' Non-Current Deffered Revenue (Quarterly) stood at $27.4 million in 2021, then decreased by 28.80% to $19.5 million in 2022, then slumped by 58.01% to $8.2 million in 2023, then crashed by 30.45% to $5.7 million in 2024, then decreased by 27.78% to $5.8 million in 2025.
  • Its last three reported values are $5.8 million in Q3 2025, $11.6 million for Q2 2025, and $13.8 million during Q1 2025.